PRLD
Prelude Therapeutics Incorporated
NASDAQ · USHealthcareBiotechnology
$4.06-3.33%
Price as of Jul 20, 2026
PRLD valuation
Prelude Therapeutics Incorporated valuation
Trailing, forward and enterprise-value multiples for the requested listing.
Forward multiples
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- 36.36x
- P/E 2028E
- 7.69x
- P/S forward
- 5.72x
Trailing multiples
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 5.37x
- Price / sales
- 19.34x
- Price / cash flow
- -7.39x
Enterprise value
- Enterprise value
- $259.5M
- EV / sales
- 15.52x
- EV / EBITDA
- -3.41x
- EV / EBIT
- -3.08x
- Market cap
- $323.4M
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.